# A Study of HS-10353 in Adult Participants With Major Depressive Disorder

> **NCT05938179** · PHASE2 · UNKNOWN · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 144 (estimated)

## Conditions studied

- Major Depressive Disorder (MDD)

## Interventions

- **DRUG:** HS-10353 30mg oral capsules
- **DRUG:** HS-10353 50mg oral capsules
- **DRUG:** Placebo for HS-10353 30mg capsules
- **DRUG:** Placebo for HS-10353 50mg capsules

## Key facts

- **NCT ID:** NCT05938179
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-31
- **Primary completion:** 2024-11-01
- **Final completion:** 2025-04-30
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2023-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05938179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05938179, "A Study of HS-10353 in Adult Participants With Major Depressive Disorder". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05938179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*